Year All 2026 2025 2024 2023 Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position September 9, 2026 PDF Version Read More Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X August 25, 2026 PDF Version Read More Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 August 11, 2026 PDF Version Read More Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea July 23, 2026 PDF Version Read More Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea June 25, 2026 PDF Version Read More Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More ASX Announcements
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position September 9, 2026 PDF Version Read More
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X August 25, 2026 PDF Version Read More
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 August 11, 2026 PDF Version Read More
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea July 23, 2026 PDF Version Read More
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea June 25, 2026 PDF Version Read More
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More
Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More
